Dempze Nancy E lowered its position in Johnson & Johnson (NYSE:JNJ) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,528 shares of the company’s stock after selling 1,043 shares during the period. Johnson & Johnson accounts for 4.0% of Dempze Nancy E’s portfolio, making the stock its 3rd largest holding. Dempze Nancy E’s holdings in Johnson & Johnson were worth $2,908,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of JNJ. Selective Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $105,000. Trust Co. of Oklahoma raised its holdings in shares of Johnson & Johnson by 37.6% in the third quarter. Trust Co. of Oklahoma now owns 8,259 shares of the company’s stock valued at $1,141,000 after acquiring an additional 2,256 shares in the last quarter. Chessman Wealth Strategies RIA bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $268,000. Canton Hathaway LLC bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $882,000. Finally, Community Bank & Trust Waco Texas raised its holdings in shares of Johnson & Johnson by 0.9% in the third quarter. Community Bank & Trust Waco Texas now owns 53,969 shares of the company’s stock valued at $7,457,000 after acquiring an additional 468 shares in the last quarter. Institutional investors own 67.33% of the company’s stock.
Several analysts recently weighed in on the company. BMO Capital Markets lifted their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Raymond James boosted their target price on shares of Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price for the company in a report on Wednesday, March 27th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $146.40.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 35.79%. The firm’s revenue was up .1% on a year-over-year basis. During the same period in the previous year, the company posted $2.06 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be issued a $0.95 dividend. The ex-dividend date is Friday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s payout ratio is currently 44.01%.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4325977/dempze-nancy-e-has-2-91-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is an overbought condition?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.